中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2010年
19期
2625-2627
,共3页
心力衰竭,充血性%甲状腺激素%心功能
心力衰竭,充血性%甲狀腺激素%心功能
심력쇠갈,충혈성%갑상선격소%심공능
Heart failure,Congestive%Thyroid hormone%Cardiac function
目的 探讨充血性心力衰竭(CHF)患者血清甲状腺激素水平的改变情况及其与病情的关系.方法 采用放射免疫法测定50例CHF患者(心功能Ⅱ级7例,Ⅲ级19例,Ⅳ级24例)和30例健康人血清三碘甲状腺原氨酸(T3)、四碘甲状腺原氨酸(T4)、游离三碘甲状腺原氨酸(FT3)、游离四碘甲状腺原氨酸(FT4)、促甲状腺激素(TSH).结果 CHF组T3、FT3含量(1.95±0.55)nmol/L、(2.20±0.39)nmol/L,低于对照组的(2.4±0.50)nmol/L、(5.89±0.45)nmol/L(t=2.415,2.325,P<0.05);治疗后T3、FT3含量(2.19±0.53)nmol/L、(3.69±0.57)nmol/L,较治疗前显著升高(t=2.375,2.405,P<0.05);CHF心功能Ⅳ级患者T3、FT3含量(1.76±0.7)nmol/L、(1.99±0.45)nmol/L,明显低于对照组(t=2.245,2.375,P<0.05);血清TT3、TT4与心功能分级呈负相关(r=-0.933,-0.383,P均<0.05),血清FT3、FT4、TSH与心功能分级均无相关性.结论 血清甲状腺激素水平的改变可作为判断CHF严重程度的指标之一.
目的 探討充血性心力衰竭(CHF)患者血清甲狀腺激素水平的改變情況及其與病情的關繫.方法 採用放射免疫法測定50例CHF患者(心功能Ⅱ級7例,Ⅲ級19例,Ⅳ級24例)和30例健康人血清三碘甲狀腺原氨痠(T3)、四碘甲狀腺原氨痠(T4)、遊離三碘甲狀腺原氨痠(FT3)、遊離四碘甲狀腺原氨痠(FT4)、促甲狀腺激素(TSH).結果 CHF組T3、FT3含量(1.95±0.55)nmol/L、(2.20±0.39)nmol/L,低于對照組的(2.4±0.50)nmol/L、(5.89±0.45)nmol/L(t=2.415,2.325,P<0.05);治療後T3、FT3含量(2.19±0.53)nmol/L、(3.69±0.57)nmol/L,較治療前顯著升高(t=2.375,2.405,P<0.05);CHF心功能Ⅳ級患者T3、FT3含量(1.76±0.7)nmol/L、(1.99±0.45)nmol/L,明顯低于對照組(t=2.245,2.375,P<0.05);血清TT3、TT4與心功能分級呈負相關(r=-0.933,-0.383,P均<0.05),血清FT3、FT4、TSH與心功能分級均無相關性.結論 血清甲狀腺激素水平的改變可作為判斷CHF嚴重程度的指標之一.
목적 탐토충혈성심력쇠갈(CHF)환자혈청갑상선격소수평적개변정황급기여병정적관계.방법 채용방사면역법측정50례CHF환자(심공능Ⅱ급7례,Ⅲ급19례,Ⅳ급24례)화30례건강인혈청삼전갑상선원안산(T3)、사전갑상선원안산(T4)、유리삼전갑상선원안산(FT3)、유리사전갑상선원안산(FT4)、촉갑상선격소(TSH).결과 CHF조T3、FT3함량(1.95±0.55)nmol/L、(2.20±0.39)nmol/L,저우대조조적(2.4±0.50)nmol/L、(5.89±0.45)nmol/L(t=2.415,2.325,P<0.05);치료후T3、FT3함량(2.19±0.53)nmol/L、(3.69±0.57)nmol/L,교치료전현저승고(t=2.375,2.405,P<0.05);CHF심공능Ⅳ급환자T3、FT3함량(1.76±0.7)nmol/L、(1.99±0.45)nmol/L,명현저우대조조(t=2.245,2.375,P<0.05);혈청TT3、TT4여심공능분급정부상관(r=-0.933,-0.383,P균<0.05),혈청FT3、FT4、TSH여심공능분급균무상관성.결론 혈청갑상선격소수평적개변가작위판단CHF엄중정도적지표지일.
Objective To investigate the clinical significance between congestive heart failure (CHF) and serum thyroxine. Methods 50 patients with CHF (7 cases of grade Ⅱ heart function,grade Ⅲ 19 cases,grade Ⅳ 24)and 30 normal persons wre selected. The serum triiodothyronine( T3 ), four-triiodothyronine( T4 ), free triiodothyronine (FT3), free triiodothyronine (FT4), thyroid stimulating hormone TSH were determined by radioimmunoassay. Results The T3, FT3 contens ( 1.95 ± 0.55) nmol/L, (2.20 ± 0.39 ) pmol/L in CHF group were lower than the control group (2.4 ± 0.50) nmol/L, ( 5.89 ± 0. 45 ) pmol/L ( t = 2. 415,2. 325, P < 0.05 ); The T3, FT3 contens ( 2.19 ± 0. 53 )nmol/L,(3.69 ± 0.57)pmol/L after treatment were significantly higher than that before treatment (t =2. 375,2. 405, P < 0.05 ); The T3, FT3 contens in cardiac function with stage Ⅳ ( 1.76 ± 0.7) nmol/L, ( 1.99 ± 0. 45 ) pmol/L were significantly lower than the control group( t = 2.245,2. 375, P < 0.05 ); Serum TT3, TT4 and cardiac function was negatively correlated ( r = -0.933, -0.383, all P < 0.05 ) , serum FT3, FT4,TSH and cardiac function were not correlated. Conclusion The changes of serum thyroid level could be used as an index of the severity of heart failure.
